200454 Search Results


wt5260 083850 transposase 837  (ATCC)
91
ATCC wt5260 083850 transposase 837
Wt5260 083850 Transposase 837, supplied by ATCC, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/wt5260 083850 transposase 837/product/ATCC
Average 91 stars, based on 1 article reviews
wt5260 083850 transposase 837 - by Bioz Stars, 2026-06
91/100 stars
  Buy from Supplier
goat anti kainic acid ka type 2 ka2 receptor  (Santa Cruz Biotechnology)
92
Santa Cruz Biotechnology goat anti kainic acid ka type 2 ka2 receptor
Figure 5 <t>KA2</t> receptor immunoreactivity patterns are abnormal in the hippocampi of thimerosal-treated SJL mice. Coronal sections of hippocampus, 5 wks PN. (a and c) SJL Control, KA2 IHC; (b and d) SJL Thim-vax, KA2 IHC. Regions of CA1 represented in (c and d) are marked (white box) in (a and b). DG, dentate gyrus; sr, stratum radiatum; pcl, pyramidal cell layer. Black bars represent 100 mm; white bars, 50 mm. (a) SJL Control. Note the relative absence of staining in pcl of CA1 subfield. (b) SJL Thim-vax. Reduced KA2 immunostaining is noted in sr of CA1, with increased staining in sr of CA3 and in pcl of CA1 and CA2 relative to SJL Control. (c) SJL Control. Note the parallel orientation of fibers in sr. (d) SJL Thim-vax. Increased staining is seen on CA1 pyramidal neurons relative to that in SJL Control.
Goat Anti Kainic Acid Ka Type 2 Ka2 Receptor, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti kainic acid ka type 2 ka2 receptor/product/Santa Cruz Biotechnology
Average 92 stars, based on 1 article reviews
goat anti kainic acid ka type 2 ka2 receptor - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier

Image Search Results


Figure 5 KA2 receptor immunoreactivity patterns are abnormal in the hippocampi of thimerosal-treated SJL mice. Coronal sections of hippocampus, 5 wks PN. (a and c) SJL Control, KA2 IHC; (b and d) SJL Thim-vax, KA2 IHC. Regions of CA1 represented in (c and d) are marked (white box) in (a and b). DG, dentate gyrus; sr, stratum radiatum; pcl, pyramidal cell layer. Black bars represent 100 mm; white bars, 50 mm. (a) SJL Control. Note the relative absence of staining in pcl of CA1 subfield. (b) SJL Thim-vax. Reduced KA2 immunostaining is noted in sr of CA1, with increased staining in sr of CA3 and in pcl of CA1 and CA2 relative to SJL Control. (c) SJL Control. Note the parallel orientation of fibers in sr. (d) SJL Thim-vax. Increased staining is seen on CA1 pyramidal neurons relative to that in SJL Control.

Journal: Molecular psychiatry

Article Title: Neurotoxic effects of postnatal thimerosal are mouse strain dependent.

doi: 10.1038/sj.mp.4001529

Figure Lengend Snippet: Figure 5 KA2 receptor immunoreactivity patterns are abnormal in the hippocampi of thimerosal-treated SJL mice. Coronal sections of hippocampus, 5 wks PN. (a and c) SJL Control, KA2 IHC; (b and d) SJL Thim-vax, KA2 IHC. Regions of CA1 represented in (c and d) are marked (white box) in (a and b). DG, dentate gyrus; sr, stratum radiatum; pcl, pyramidal cell layer. Black bars represent 100 mm; white bars, 50 mm. (a) SJL Control. Note the relative absence of staining in pcl of CA1 subfield. (b) SJL Thim-vax. Reduced KA2 immunostaining is noted in sr of CA1, with increased staining in sr of CA3 and in pcl of CA1 and CA2 relative to SJL Control. (c) SJL Control. Note the parallel orientation of fibers in sr. (d) SJL Thim-vax. Increased staining is seen on CA1 pyramidal neurons relative to that in SJL Control.

Article Snippet: IHC was performed using the primary polyclonal antibodies: rabbit antiN-methyl-D-aspartate (NMDA) receptor (NR) type 1 (NR1, 1 : 25 dilution), rabbit anti-NR2B (1 : 750 dilution, Chemicon); goat anti-kainic acid (KA) type 2 (KA2) receptor (1 : 50 dilution), goat anti-excitatory amino-acid transporter (EAAT) type 2 (EAAT2, 1 : 150 dilution), and goat anti-EAAT3 (1 : 25 dilution, Santa Cruz).

Techniques: Control, Staining, Immunostaining